The Program described in the grant application will train postdoctoral (predominantly MD or MD/PhD) fellows who completed their clinical training and will be returning to the laboratory to pursue their career goal of establishing themselves as independent medical research scientists in the field of hematopoietic cell transplantation. The main applicant pool is individuals who completed Fellowships in Blood and Marrow Transplantation, or Hematology/Oncology, yet fellows from other clinical divisions or applications from PhD post-doctoral fellows whose research has direct relevance to our field and who have displayed an excellent record of pre- doctoral achievement are also encouraged to apply. Each year the training grant supports two trainees who follow a core educational curriculum, and a highly structured mentoring program that is focused on creating realistic individual development plans to enable their transition to academic faculty with careers as independently funded researchers in the field. The active growth of research into the biology of cellular and immunotherapy for treatment of cancer and other diseases, and the translation of preclinical concepts to the clinical setting demands highly trained physician scientists which justifies the unique focus of this training program.
This mission of the Training Program is to support postdoctoral (predominantly MD/PhDs) trainees who completed their clinical training and are pursuing their goal of becoming indenedently funded physician scientists in the biology of hematopoietic cell transplantation. The Training Program follows a planned core curriculum and a highly structured mentoring program that is focused on transitioning trainees to their first faculty appointment such that they will have developed the tools and experience to become leaders in the field and continue to explore novel strategies to cure cancer and other disorders.
|Msaouel, Pavlos; Lam, Anthony P; Gundabolu, Krishna et al. (2014) Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99:930-6|
|Dunleavy, Kieron; Pittaluga, Stefania; Maeda, Lauren S et al. (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408-16|
|Lam, Anthony P; Gundabolu, Krishna; Sridharan, Ashwin et al. (2013) Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 88:E245-9|
|Meyer, Everett H; Hsu, Andro R; Liliental, Joanna et al. (2013) A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease. Blood 121:4955-62|
|Logan, Aaron C; Weissman, Irving L; Shizuru, Judith A (2012) The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol 24:640-8|
|Warsch, Sean; Hosein, Peter J; Maeda, Lauren S et al. (2012) A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 53:1299-1305|
|Herges, Katja; de Jong, Brigit A; Kolkowitz, Ilan et al. (2012) Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler 18:398-408|
|Gill, Saar; Vasey, Adrianne E; De Souza, Alysha et al. (2012) Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119:5758-68|
|Maeda, Lauren S; Lee, Mark; Advani, Ranjana H (2011) Current concepts and controversies in the management of early stage Hodgkin lymphoma. Leuk Lymphoma 52:962-71|
|Chen, George L; Arai, Sally; Flowers, Mary E D et al. (2011) A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 118:4070-8|
Showing the most recent 10 out of 17 publications